| Popis: |
Drug-drug interactions are common with traditional prescription medications especially in patients older than 65 years of age and/or those with multiple chronic conditions. The risk of a potential drug-drug interaction rises with the increasing number of medications. Drug interactions can be classified as either pharmacokinetic or pharmacodynamic. There is less evidence of documented drug interactions with cannabinoids either delta 9-tetrahydrocannabinol (THC) or cannabidiol (CBD). Due to their metabolism through the liver, THC and CBD have the potential to cause significant drug-drug interactions; however, limited data exist documenting these interactions except those generated from clinical pharmacokinetic studies with Epidiolex® (cannabidiol). Therefore, we must extrapolate potential drug-drug interactions through an understanding of the pharmacokinetics of both the “victim” drug and cannabis. In this chapter, we will review what is known about drug-drug interactions and explore their clinical significance. |
